Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma

Sponsor
Lymphoma Study Association
Study ID
NCT00169195
Phase
PHASE2
Status
Completed

Conditions

  • Diffuse Large Cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The Purpose of this study is to evaluate the efficacy and the safety of R-GEMOX in refractory/relapsed patients with CD20-positive large B-cell lymphoma who are not eligible for autologous transplantation.

Key Dates

Start date
Apr 30, 2003
Status verified
Sep 2015
Primary completion
Nov 30, 2012
Completion
Nov 30, 2012

Study Design

Enrollment
49 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: R-GEMOX
    Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)

Primary Outcome Measure

Overall response rate (ORR) (complete response, [CR]; unconfirmed complete response, [CRu] and partial response, [PR]) [ Time Frame: 8 weeks ]

Related Studies